(Q34188829)

31 July 2017

1 reference

title

Statin therapy: where are we? Where do we go next? (English)

1 reference

31 July 2017

1 reference

Gotto AM Jr

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

American Journal of Cardiology

31 July 2017

published in

1 reference

31 July 2017

volume

87

1 reference

31 July 2017

issue

5A

1 reference

31 July 2017

page(s)

13B-18B

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Clinical lipidology at the end of the millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901450-3

10.1016/S0002-9149(01)01450-3

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference